Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Report 2026

Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview

• Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs market size has reached to $2.57 billion in 2025 • Expected to grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Impact Of Rising Autoimmune Disease Prevalence On The Market • Market Trend: Oral S1PR Modulators Enhance Patient Compliance And Treatment Efficacy In Autoimmune Diseases • Asia-Pacific was the largest region in 2025.

What Is Covered Under Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market?

Sphingosine 1 phosphate receptor (S1PR) modulator drugs refer to a class of therapeutic agents that specifically target sphingosine-1-phosphate (S1P) receptors, a family of G-protein-coupled receptors involved in critical cellular processes. These drugs modulate the activity of S1P receptors, which play a key role in immune cell trafficking, vascular function, and inflammation. The main types of sphingosine 1 phosphate receptor (S1PR) modulator drugs are fingolimod and ozanimod. Fingolimod is an oral medication used to treat multiple sclerosis (MS) by modulating the immune system to prevent nerve damage caused by the disease. These drugs are available in various routes of administration, including oral, injectable, and topical forms, and are used in the treatment of multiple sclerosis, cardiovascular diseases, and transplant rejection. They are primarily used in hospitals, rehabilitation centers, and retail pharmacies.

What Is The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Growth Forecast?

The sphingosine 1 phosphate receptor (s1pr) modulator drugs market size is expected to see strong growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growing multiple sclerosis patient population, expansion of s1pr drug pipelines, increased preference for oral immunotherapies, rising autoimmune disease diagnosis rates, growing specialty clinic adoption. Major trends in the forecast period include growing use of immune cell trafficking modulators, increasing adoption in multiple sclerosis treatment, expansion of oral immunomodulatory therapies, rising focus on targeted immune modulation, increased use in chronic autoimmune conditions.

Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Segmentation

1) By Type: Fingolimod, Ozanimod 2) By Route Of Administration: Oral, Injectable 3) By Application: Multiple Sclerosis, Cardiovascular Diseases, Transplant Rejection 4) By End User: Hospital, Rehabilitation Centres, Retail Pharmacies Subsegments: 1) By Fingolimod: Branded Formulations, Generic Formulations 2) By Ozanimod: Oral Capsules, Other Formulations

What Is The Driver Of The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market?

The rising prevalence of autoimmune diseases is expected to propel the growth of the sphingosine 1 phosphate receptor (S1PR) modulator drugs market going forward. Autoimmune diseases are conditions where the immune system mistakenly attacks the body's own healthy cells, causing inflammation and damage. The rising prevalence of autoimmune diseases is driven by genetic factors, environmental triggers, lifestyle changes, and improved diagnostics. Sphingosine 1-Phosphate Receptor (S1PR) modulator drugs are used in autoimmune diseases to regulate immune cell migration, reducing inflammation in conditions like multiple sclerosis and ulcerative colitis. For instance, in February 2025, according to the Australian Broadcasting Corporation, an Australia-based national public broadcaster, inflammatory bowel disease currently impacts almost 180,000 Australians, with Crohn's Disease affecting 93,700 and Ulcerative Colitis affecting 80,430 individuals, and the total number is expected to rise to 200,000 in the next 10 years. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market.

Key Players In The Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market

Major companies operating in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market are Novartis International AG, Bristol Myers Squibb Company, Celgene Corporation, Biogen Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Ventyx Biosciences Inc., Arena Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., KYORIN Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., Vanda Pharmaceuticals Inc., Juvisé Pharmaceuticals, Priothera Limited, Teva Pharmaceutical Industries Ltd.

Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Trends and Insights

Major companies operating in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market are advancing oral therapies, such as etrasimod (VELSIPITY), to boost patient adherence, enhance efficacy, and expand treatment reach in immuno inflammatory disorders. An oral S1PR modulator is a small molecule pill that selectively binds to S1P receptors to modulate immune cell trafficking and reduce inflammation. For instance, in October 2023, Pfizer, a US based pharmaceutical and biotechnology company, received FDA approval for VELSIPITY (etrasimod) for moderately to severely active ulcerative colitis; the once daily drug offers high receptor selectivity, a favorable safety profile, and convenient oral dosing.

What Are Latest Mergers And Acquisitions In The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market?

In December 2023, Vanda Pharmaceuticals, a US-based pharmaceutical company, acquired U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition aims to enhance Vanda's portfolio with an innovative therapy for relapsing MS, a condition with increasing prevalence and a significant unmet medical need. Actelion Pharmaceuticals Ltd. is a Switzerland-based biopharmaceutical company focused on developing sphingosine 1-phosphate receptor (S1PR) modulator drugs for various diseases.

Regional Insights

Asia-Pacific was the largest region in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market?

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market consists of sales of non-selective S1PR modulators, selective S1PR1 modulators, and next-generation and experimental S1PR modulators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Report 2026?

The sphingosine 1 phosphate receptor (s1pr) modulator drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sphingosine 1 phosphate receptor (s1pr) modulator drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.